Nanotheranostics for personalized medicine

Nanotheranostics, the integration of diagnostic and therapeutic function in one system using the benefits of nanotechnology, is extremely attractive for personalized medicine. Because treating cancer is not a one-size-fits-all scenario, it requires therapy to be adapted to the patient’s specific biomolecules. Personalized and precision medicine (PM) does just that. It identifies biomarkers to gain an understanding of the diagnosis and in turn treating the specific disorder based on the precise diagnosis. By predominantly utilizing the unique properties of nanoparticles to achieve biomarker identification and drug delivery, nanotheranostics can be applied to noninvasively discover and target image biomarkers and further deliver treatment based on the biomarker distribution. This is a large and hopeful role theranostics must fill. However, as described in this expert opinion, current nanotechnology-based theranostics systems engineered for PM applications are not yet sufficient. PM is an ever-growing field that will be a driving force for future discoveries in biomedicine, especially cancer theranostics. In this article, the authors dissect the requirements for successful nanotheranostics-based PM.

[1]  Yosef Yarden,et al.  Molecular mechanisms underlying ErbB2/HER2 action in breast cancer , 2000, Oncogene.

[2]  A. Groves,et al.  Non-[18F]FDG PET in clinical oncology. , 2007, The Lancet. Oncology.

[3]  Erkki Ruoslahti,et al.  Remotely Triggered Release from Magnetic Nanoparticles , 2007 .

[4]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[5]  J. Ho,et al.  Nanotheranostics – a review of recent publications , 2012, International journal of nanomedicine.

[6]  H Akita,et al.  Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid , 2007, Gene Therapy.

[7]  Jin Xie,et al.  Nanoparticle-based theranostic agents. , 2010, Advanced drug delivery reviews.

[8]  I. Velikyan.  Molecular Imaging and Radiotherapy: Theranostics for Personalized Patient Management , 2012, Theranostics.

[9]  Kwangmeyung Kim,et al.  Multiplex imaging of an intracellular proteolytic cascade by using a broad-spectrum nanoquencher. , 2012, Angewandte Chemie.

[10]  Chenjie Xu,et al.  Ultrasmall c(RGDyK)-coated Fe3O4 nanoparticles and their specific targeting to integrin alpha(v)beta3-rich tumor cells. , 2008, Journal of the American Chemical Society.

[11]  Bonnie F. Sloane,et al.  Pericellular cathepsin B and malignant progression , 2003, Cancer and Metastasis Reviews.

[12]  Patrick Couvreur,et al.  Nanotheranostics for personalized medicine. , 2016, Advanced drug delivery reviews.

[13]  S. Larson,et al.  The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development , 2005, Clinical Cancer Research.

[14]  R. Tenne,et al.  Polymer-assisted fabrication of nanoparticles and nanocomposites , 2008 .

[15]  Yoon Yeo,et al.  Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. , 2009, Molecular pharmaceutics.

[16]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[17]  W. Sadee,et al.  Pharmacogenetics/genomics and personalized medicine. , 2005, Human molecular genetics.

[18]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[19]  R. Langer,et al.  Nanomedicine: developing smarter therapeutic and diagnostic modalities. , 2006, Advanced drug delivery reviews.

[20]  Marcel Leist,et al.  Four deaths and a funeral: from caspases to alternative mechanisms , 2001, Nature Reviews Molecular Cell Biology.

[21]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[22]  Yi Zhang,et al.  Quantum Dot Enabled Molecular Sensing and Diagnostics , 2012, Theranostics.

[23]  Tycho Heimbach,et al.  Prodrugs: design and clinical applications , 2008, Nature Reviews Drug Discovery.

[24]  V. Ghole,et al.  Proteomic profiling and interactome analysis of ER-positive/HER2/neu negative invasive ductal carcinoma of the breast: towards proteomics biomarkers. , 2013, Omics : a journal of integrative biology.

[25]  Sanjiv S Gambhir,et al.  Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. , 2006, Nano letters.

[26]  Wenjin Xu,et al.  Gold Nanorods Conjugated with Doxorubicin and cRGD for Combined Anticancer Drug Delivery and PET Imaging , 2012, Theranostics.

[27]  R. Reba,et al.  Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine. , 2008, Drug discovery today.

[28]  Seulki Lee,et al.  Activatable molecular probes for cancer imaging. , 2010, Current topics in medicinal chemistry.

[29]  Sanjay Tyagi,et al.  Molecular Beacons: Probes that Fluoresce upon Hybridization , 1996, Nature Biotechnology.

[30]  Yongdoo Choi,et al.  Photosensitizer-Conjugated Gold Nanorods for Enzyme-Activatable Fluorescence Imaging and Photodynamic Therapy , 2012, Theranostics.

[31]  Luis M Liz-Marzán,et al.  Shape control in gold nanoparticle synthesis. , 2008, Chemical Society reviews.

[32]  David Issadore,et al.  Magnetic Nanoparticles and microNMR for Diagnostic Applications , 2012, Theranostics.

[33]  Bonnie F. Sloane,et al.  Immunohistochemical localization of cathepsin B in neoplastic human prostate , 1995, The Prostate.

[34]  D. Scheinberg,et al.  Monoclonal antibody therapy of cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[35]  Z. Chen,et al.  Magnetic Nanoparticle-Based Hyperthermia for Head & Neck Cancer in Mouse Models , 2012, Theranostics.

[36]  F. Vogenberg,et al.  Personalized medicine: part 1: evolution and development into theranostics. , 2010, P & T : a peer-reviewed journal for formulary management.

[37]  Taekhoon Kim,et al.  Activatable nanomaterials at the forefront of biomedical sciences , 2010 .

[38]  C. Haynes,et al.  Nanosphere Lithography: A Versatile Nanofabrication Tool for Studies of Size-Dependent Nanoparticle Optics , 2001 .

[39]  I. Fichtner,et al.  A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. , 2003, Cancer research.

[40]  D Tripathy,et al.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Ki Young Choi,et al.  Protease-Activated Drug Development , 2012, Theranostics.

[42]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[43]  Kai Yang,et al.  Multimodal Imaging Guided Photothermal Therapy using Functionalized Graphene Nanosheets Anchored with Magnetic Nanoparticles , 2012, Advanced materials.

[44]  K. Aldape,et al.  A model of molecular interactions on short oligonucleotide microarrays , 2003, Nature Biotechnology.

[45]  R. Brooks,et al.  Relaxometry and magnetometry of the MR contrast agent MION‐46L , 1999, Magnetic resonance in medicine.

[46]  N. Morgan,et al.  Electrochemical immunosensors for detection of cancer protein biomarkers. , 2012, ACS nano.

[47]  Gert Storm,et al.  Gold nanoparticles in theranostic oncology: current state-of-the-art , 2012, Expert opinion on drug delivery.

[48]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[49]  Xiaoyuan Chen,et al.  Introducing Theranostics Journal - From the Editor-in-Chief , 2011, Theranostics.

[50]  Jin Xie,et al.  Magnetic Nanoparticle-Based Theranostics , 2012, Theranostics.

[51]  P. Senter.  Potent antibody drug conjugates for cancer therapy. , 2009, Current opinion in chemical biology.

[52]  M. Swierczewska,et al.  Research Spotlight: Moving theranostics from bench to bedside in an interdisciplinary research team , 2011 .

[53]  M. Dowsett,et al.  Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centres , 2003, The Journal of pathology.

[54]  Lixin Lang,et al.  Quantitative Analysis and Parametric Imaging of 18F-Labeled Monomeric and Dimeric RGD Peptides Using Compartment Model , 2012, Molecular Imaging and Biology.

[55]  Wafik S El-Deiry,et al.  Imaging and oncologic drug development. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Rhona A. Berganos,et al.  First Experience with Clinical-Grade [18F]FPP(RGD)2: An Automated Multi-step Radiosynthesis for Clinical PET Studies , 2012, Molecular Imaging and Biology.

[57]  Shuji Ogino,et al.  Optical Imaging with a Cathepsin B Activated Probe for the Enhanced Detection of Esophageal Adenocarcinoma by Dual Channel Fluorescent Upper GI Endoscopy , 2012, Theranostics.

[58]  Xiaoyuan Chen.  One Year after a Successful Start of Theranostics , 2012, Theranostics.

[59]  A. Alivisatos.  Semiconductor Clusters, Nanocrystals, and Quantum Dots , 1996, Science.

[60]  Magdalena Swierczewska,et al.  Inorganic Nanoparticles for Multimodal Molecular Imaging , 2011, Molecular imaging.

[61]  Ick Chan Kwon,et al.  Optical Imaging of Cancer-Related Proteases Using Near-Infrared Fluorescence Matrix Metalloproteinase-Sensitive and Cathepsin B-Sensitive Probes , 2012, Theranostics.

[62]  G. Ginsburg,et al.  The path to personalized medicine. , 2002, Current opinion in chemical biology.

[63]  Ick Chan Kwon,et al.  Cell-permeable and biocompatible polymeric nanoparticles for apoptosis imaging. , 2006, Journal of the American Chemical Society.

[64]  M. Rosenblum,et al.  Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. , 2012, Biomaterials.

[65]  Valentyn Novosad,et al.  Biofunctionalized magnetic-vortex microdiscs for targeted cancer-cell destruction. , 2010, Nature materials.

[66]  Emanuel Petricoin,et al.  Molecular profiling of human cancer , 2000, Nature Reviews Genetics.

[67]  É. Duguet,et al.  Magnetic nanoparticle design for medical diagnosis and therapy , 2004 .

[68]  I. Kwon,et al.  Phthalocyanine-Aggregated Polymeric Nanoparticles as Tumor-Homing Near-Infrared Absorbers for Photothermal Therapy of Cancer , 2012, Theranostics.

[69]  W. Cai,et al.  Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. , 2006, Anti-cancer agents in medicinal chemistry.

[70]  Wayne M. Mullett,et al.  Nanomedicine in action: an overview of cancer nanomedicine on the market and in clinical trials , 2013 .

[71]  Beom Suk Lee,et al.  Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. , 2012, Biomaterials.

[72]  Ido D. Weiss,et al.  MicroPET Imaging of Integrin αvβ3 Expressing Tumors Using 89Zr-RGD Peptides , 2010, Molecular Imaging and Biology.

[73]  Seulki Lee,et al.  Peptide-based probes for targeted molecular imaging. , 2010, Biochemistry.

[74]  Gang Liu,et al.  High-sensitivity nanosensors for biomarker detection. , 2012, Chemical Society reviews.

[75]  M. Melancon,et al.  Cancer theranostics with near-infrared light-activatable multimodal nanoparticles. , 2011, Accounts of chemical research.

[76]  R. V. Duyne,et al.  Nanosphere Lithography: Size-Tunable Silver Nanoparticle and Surface Cluster Arrays , 1999 .

[77]  C. López-Otín,et al.  Emerging roles of proteases in tumour suppression , 2007, Nature Reviews Cancer.

[78]  M. Tan,et al.  Integrin Targeted MR Imaging , 2011, Theranostics.

[79]  Ryan Abo,et al.  Simultaneous analysis of multiple data types in pharmacogenomic studies using weighted sparse canonical correlation analysis. , 2012, Omics : a journal of integrative biology.

[80]  Kwangmeyung Kim,et al.  Real time, high resolution video imaging of apoptosis in single cells with a polymeric nanoprobe. , 2011, Bioconjugate chemistry.

[81]  N. Sampas,et al.  Molecular classification of cutaneous malignant melanoma by gene expression profiling , 2000, Nature.

[82]  Ick Chan Kwon,et al.  A near-infrared-fluorescence-quenched gold-nanoparticle imaging probe for in vivo drug screening and protease activity determination. , 2008, Angewandte Chemie.

[83]  Shuming Nie,et al.  Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry , 2007, Nature Protocols.

[84]  Jinwoo Cheon,et al.  All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. , 2009, Angewandte Chemie.

[85]  Xiaoyuan Chen,et al.  PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTA-PRGD2 , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[86]  Weibo Cai,et al.  Anti-Angiogenic Cancer Therapy Based on Integrin αvβ3 Antagonism , 2006 .